PMID- 37919851
OWN - NLM
STAT- MEDLINE
DCOM- 20231106
LR  - 20231110
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 44
IP  - 6
DP  - 2023 Nov 1
TI  - Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous 
      urticaria.
PG  - 429-435
LID - 10.2500/aap.2023.44.230051 [doi]
AB  - Background: Endothelin-1 (ET-1) and interleukin-33 (IL-33) can modulate the 
      activation of mast cells and basophils in the pathophysiology of allergic 
      diseases, interplaying with other mediators of "low-grade inflammation." 
      Objective: To compare ET-1, IL-33, the neutrophil-lymphocyte ratio (NLR), 
      eosinophil-lymphocyte ratio (ELR), platelet-lymphocyte ratio (PLR), 
      eosinophil-basophil ratio (EBR), systemic immune inflammation index (SII), and 
      system inflammation response index (SIRI) in patients with chronic spontaneous 
      urticaria (CSU) and are antihistamine sensitive (AHS), antihistamine resistant 
      (AHR), omalizumab sensitive (OmS), and omalizumab resistant (OmR). Methods: A 
      prospective observational study enrolled 68 consecutive patients with CSU 
      diagnosed and managed according to the dermatology section of the European 
      Academy of Allergology and Clinical Immunology (EAACI), the European Union funded 
      network of excellence, the Global Allergy and Asthma European Network (GA2LEN), 
      the European Dermatology Forum (EDF), and the World Allergy Organization 
      guidelines. Patients with a urticaria control test score of >12 are considered 
      treatment sensitive, and </= 12 are considered resistant. The control group 
      consisted of 20 sex-matched subjects without urticarial diseases. Total 
      immunoglobulin E (IgE), antinuclear antibodies (ANA), thyroid stimulating 
      hormone, antithyroid peroxidase, mean platelet volume (MPV), NLR, ELR, PLR, EBR, 
      SII, SIRI, ET-1, and IL-33 were measured at the study entry and compared between 
      the study groups. Results: Thirty AHS group, 38 AHR group, and 20 control group 
      patients were included. The AHS, AHR, and control groups did not differ in 
      demographic parameters, but the CSU groups were characterized by higher 
      indicators of inflammation. In comparison with the AHS group, the AHR group was 
      characterized by higher levels of IL-33 (p = 0.007), ET-1 (p = 0.032), C-reactive 
      protein (p = 0.016), MPV (p = 0.002), and higher rates of positive ANA (p = 
      0.019). Of the 38 patients from the AHR group, 30 (79%) were included in the OmS 
      group and 8 (21%) were included in the OmR group. The OmR group was characterized 
      by higher levels of C-reactive protein (p = 0.022), EBR (p < 0.001), higher rates 
      of ANA (p = 0.004), and lower levels of ET-1 (p = 0.025) than the OmS group. 
      Conclusion: Our study did not confirm NRL, PRL, SII, and SIRI, PLR as the 
      biomarkers of treatment response to antihistamines and/or omalizumab in CSU. 
      Higher blood levels of IL-33 and ET-1 characterize AHR CSU.
FAU - Kulumbegov, Bidzina
AU  - Kulumbegov B
AD  - From the Center of Allergy and Immunology, Tbilisi, Georgia.
FAU - Chikovani, Tinatin
AU  - Chikovani T
AD  - Immunology Department, Tbilisi State Medical University, Tbilisi, Georgia, and.
FAU - Gotua, Maia
AU  - Gotua M
AD  - From the Center of Allergy and Immunology, Tbilisi, Georgia.
FAU - Kikodze, Nino
AU  - Kikodze N
AD  - Immunology Department, Tbilisi State Medical University, Tbilisi, Georgia, and.
FAU - Magen, Eli
AU  - Magen E
AD  - Assuta Ashdod University Medical Center, Ben Gurion University of the Negev, 
      Ashdod, Israel.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 2P471X1Z11 (Omalizumab)
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Interleukin-33)
RN  - 0 (Endothelin-1)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 0 (Histamine Antagonists)
RN  - 0 (Histamine H1 Antagonists)
SB  - IM
MH  - Humans
MH  - Omalizumab/therapeutic use
MH  - *Anti-Allergic Agents/therapeutic use
MH  - Interleukin-33
MH  - Endothelin-1/therapeutic use
MH  - C-Reactive Protein
MH  - *Chronic Urticaria/drug therapy
MH  - *Urticaria/drug therapy
MH  - Histamine Antagonists/therapeutic use
MH  - Histamine H1 Antagonists/therapeutic use
MH  - Inflammation/drug therapy
MH  - Chronic Disease
EDAT- 2023/11/03 06:45
MHDA- 2023/11/06 06:43
CRDT- 2023/11/03 00:59
PHST- 2023/11/06 06:43 [medline]
PHST- 2023/11/03 06:45 [pubmed]
PHST- 2023/11/03 00:59 [entrez]
AID - 10.2500/aap.2023.44.230051 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2023 Nov 1;44(6):429-435. doi: 10.2500/aap.2023.44.230051.